Downloads: 84

Files in This Item:
File Description SizeFormat 
circj.CJ-19-0515.pdf5.95 MBAdobe PDFView/Open
Title: Cancer-Associated Venous Thromboembolism in the Real World --From the COMMAND VTE Registry--
Authors: Sakamoto, Jiro
Yamashita, Yugo  kyouindb  KAKEN_id
Morimoto, Takeshi
Amano, Hidewo
Takase, Toru
Hiramori, Seiichi
Kim, Kitae
Oi, Maki
Akao, Masaharu
Kobayashi, Yohei
Toyofuku, Mamoru
Izumi, Toshiaki
Tada, Tomohisa
Chen, Po-Min
Murata, Koichiro
Tsuyuki, Yoshiaki
Saga, Syunsuke
Nishimoto, Yuji
Sasa, Tomoki
Kinoshita, Minako
Togi, Kiyonori
Mabuchi, Hiroshi
Takabayashi, Kensuke
Yoshikawa, Yusuke
Shiomi, Hiroki  kyouindb  KAKEN_id
Kato, Takao  kyouindb  KAKEN_id  orcid (unconfirmed)
Makiyama, Takeru
Ono, Koh
Tamura, Toshihiro
Nakagawa, Yoshihisa
Kimura, Takeshi
Author's alias: 山下, 侑吾
塩見, 紘樹
加藤, 貴雄
牧山, 武
尾野, 亘
木村, 剛
Keywords: Bleeding
Venous thromboembolism
Issue Date: 25-Oct-2019
Publisher: Japanese Circulation Society
Journal title: Circulation Journal
Volume: 83
Issue: 11
Start page: 2271
End page: 2281
Abstract: Background:There is a paucity of data on the management and prognosis of cancer-associated venous thromboembolism (VTE), leading to uncertainty about optimal management strategies. Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3, 027 consecutive acute symptomatic VTE patients in Japan between 2010 and 2014. We divided the entire cohort into 3 groups: active cancer (n=695, 23%), history of cancer (n=243, 8%), and no history of cancer (n=2089, 69%). The rate of anticoagulation discontinuation was higher in patients with active cancer (43.5%, 27.0%, and 27.0%, respectively, at 1 year, P<0.001). The cumulative 5-year incidences of recurrent VTE, major bleeding, and all-cause death were higher in patients with active cancer (recurrent VTE: 17.7%, 10.2%, and 8.6%, P<0.001; major bleeding: 26.6%, 8.8%, and 9.3%, P<0.001; all-cause death: 73.1%, 28.6%, 14.6%, P<0.001). Among the 4 groups classified according to active cancer status, the cumulative 1-year incidence of recurrent VTE was higher in the metastasis group (terminal stage group: 6.4%, metastasis group: 22.1%, under chemotherapy group: 10.8%, and other group: 5.8%, P<0.001). Conclusions:In a current real-world VTE registry, patients with active cancer had higher risk for VTE recurrence, bleeding, and death, with variations according to cancer status, than patients without active cancer. Anticoagulation therapy was frequently discontinued prematurely in patients with active cancer in discordance with current guideline recommendations.
Publisher permitted to deposit this paper on this repository.
DOI(Published Version): 10.1253/circj.CJ-19-0515
PubMed ID: 31548438
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.